Valence ロゴ
人気
ログイン
Loading data for BCTXL — first visit, this takes a few seconds.

ウォッチリストに追加

BriaCell Therapeutics Cor...

NasdaqCM: BCTXL · リアルタイム株価 · USD
1.03
+0.07 (7.29%)
終値時点： Aug 28, 2026, 7:53 PM

株価、主要な数字、最新ニュースをひとまとめにしたページです。

BriaCell Therapeutics Corp.（BCTXL）の株価・分析・データ

7.29%

データがありません

買気配n/a
時価総額n/a
売上高（TTM）n/a
純利益（TTM）-30.68M
1.52
n/a
n/a
n/a
PBR（TTM）0.29
PSR（TTM）n/a
決算発表日n/a
売気配n/a
出来高393
平均出来高（20日）
始値1.00
前日終値0.96
当日レンジ1.03 - 1.03
52週レンジ1.03 - 1.03
アナリストn/a
目標株価n/a
配当n/a
権利落ち日n/a

BCTXLについて

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an i...

[続きを読む]
業種
セクター
IPO日 n/a
従業員数 n/a
上場取引所 NasdaqCM
ティッカー BCTXL
ウェブサイト https://briacell.com
企業情報の全文

業績

undefined年のBriaCell Therapeuticsの売上高はn/aで、前年のn/aからundefined%の増加でした。 利益はn/aで、undefined%の増加でした。

財務諸表
news image

6日前 · InvestorsHub

BriaCell Shares Turn Volatile After Melanoma Vaccine Development Milestone

BriaCell Therapeutics (NASDAQ:BCTX) shares experienced a volatile session on Monday after the biotechnology company announced that its Bria-MEL+ melanoma vaccine candidate had reached an important gen...

news image

1か月前 · Simply Wall St.

Is CRA International’s New Bria-IMT Role Quietly Redefining Its Healthcare Moat and Pricing Power (CRAI)?

In July 2026, BriaCell Therapeutics Corp. announced it had engaged Charles River Associates (CRA International) and Kaleio, Inc. to support commercial strategy, market access evaluation, and brand pla...

news image

3か月前 · MT Newswires

BriaCell Presenting Final Phase 2, Ongoing Phase 3 Data at ASCO Meeting

BriaCell Therapeutics (BCT.TO) Monday said it is presenting final Phase 2 data from its Bria-IMT tri

news image

3か月前 · MT Newswires

BriaCell Therapeutics Completes Manufacturing Bria-PROS+ Clinical Supplies

BriaCell Therapeutics (BCT.TO), down near 1% in U.S. pre-market trade, has completed manufacturing

news image

3か月前 · MT Newswires

BriaCell Says FDA Clears Way For Bria-BRES+ Phase 1/2a Study

BriaCell Therapeutics (BCT.TO) has received FDA approval to initiate clinical evaluation of its next